Compare Crispr Therapeutics AG (CRSP) vs The Coca-Cola Co K (KO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs The Coca-Cola Co K — how do they compare? Crispr Therapeutics AG trades at $50.73 (market cap $5.06B), while The Coca-Cola Co K trades at $87.39 (market cap $369.24B). The key difference: The Coca-Cola Co K is far larger — about 73× Crispr Therapeutics AG's market cap, and The Coca-Cola Co K pays a 2.47% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and The Coca-Cola Co K for 154 Days on average.
| CRSP | KO | |
|---|---|---|
Market Cap | $5.06B | $369.24B |
Volume | 1,678,371 | 12,951,290 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $91.99 |
52-Week Low | $44.34 | $66.37 |
Typical Hold Time | 77 Days | 154 Days |
Enterprise Value | $3.48B | $396.42B |
Dividend Yield | — | 2.47% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 6.59% over 24 hours amid bearish technical signals. The company shows negative profitability metrics with -4,101.26% net income margin and -$581.60M net loss for 2025, though Q2 2026 EPS beat expectations. Recent news highlights upcoming clinical data presentations and commercial progress with CASGEVY gene therapy. Cash flow remains negative from operations but positive overall due to financing activities.
While analyst consensus remains bullish with 57.9% buy ratings and $67.83 price target, significant execution risks persist. The stock faces pressure from sustained cash burn and competitive threats, but potential catalysts include upcoming clinical data readouts and CASGEVY revenue growth. Investors should weigh high-risk biotech volatility against breakthrough therapy potential.
Coca-Cola (KO) trades at $87.77, up 1.86% today, with a bearish technical signal despite recent earnings beats. The stock shows strong profitability with a 28.56% net income margin and 44.23% ROE, supported by consistent revenue growth. Analyst consensus is bullish with a $95.75 price target, though technical indicators highlight near-term resistance at $86-$87. Recent news highlights institutional buying and stable demand trends ahead of Q3 earnings.
The outlook remains positive given KO's dividend track record and earnings momentum, but risks include regional demand volatility and high debt levels. Upside is supported by analyst targets, while technical weakness near key resistance may limit short-term gains. The stock offers value for income-focused investors despite macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About The Coca-Cola Co K
The Coca-Cola Company manufactures, markets, and distributes soft drink concentrates and syrups. The Company also distributes and markets juice and juice-drink products. Coca-Cola distributes its products to retailers and wholesalers in the United States and internationally.
Read more on KO →
